On this page
What is maca root?
Lepidium meyenii is a cruciferous plant — in the same botanical family as broccoli, radish, and turnip — grown exclusively in the Peruvian and Bolivian Andes at 3,500–4,500 metres above sea level. The swollen hypocotyl (root-like structure) is dried and powdered or gelatinised for consumption. Maca has been cultivated in the Andes for at least 2,000 years as a food staple and endurance tonic, with traditional use by Inca warriors before battle. [5]
Three colour varieties exist — yellow/cream (~60% of Peruvian harvest), red (~25%), and black (~10%) — with distinct phytochemical profiles and different pharmacological applications. Using the wrong variety for the intended application reduces efficacy. The colour distinction matters practically and is detailed in the variety comparison section. [6]
How maca works — two distinct compound families
Macamides — the libido and endocannabinoid mechanism: Macamides are N-benzyl fatty acid amides unique to Lepidium meyenii. Structurally similar to anandamide (the body's endogenous cannabinoid), they inhibit fatty acid amide hydrolase (FAAH) — the enzyme that degrades anandamide. By extending anandamide's signalling duration, macamides modulate motivation, mood, and libido via endocannabinoid pathways without directly activating cannabinoid receptors. This is the mechanism that explains maca's consistent libido benefit without any hormonal change across three independent RCTs. [1]
Glucosinolates and isothiocyanates — the endurance mechanism: Maca glucosinolates are hydrolysed by myrosinase to yield isothiocyanates — including benzyl isothiocyanate (BIT). These activate the Nrf2 antioxidant response pathway, upregulating glutathione synthesis and antioxidant enzyme expression. This is the proposed mechanism for maca's anti-fatigue effects and likely explains black maca's superior endurance data, as black maca contains the highest glucosinolate concentrations of all three varieties. [4]
Clinical evidence
| Study | Design | n | Key finding | Grade |
|---|---|---|---|---|
| Gonzales GF et al. (2002) — Andrologia doi:10.1046/j.1439-0272.2002.00519.x |
Double-blind RCT, 12 wk | 57 | Libido improved significantly at week 8 with 1,500 and 3,000 mg/day maca vs placebo. Testosterone, oestradiol, LH, FSH, prolactin: unchanged across all groups. Landmark trial establishing the non-hormonal mechanism. | A |
| Brooks NA et al. (2008) — Menopause doi:10.1097/gme.0b013e3181732953 |
Double-blind crossover, 6 wk | 14 | Maca extract significantly improved libido and sexual function in postmenopausal women with SSRI-induced sexual dysfunction. Oestrogen, FSH, androgens: all unchanged. Endocannabinoid pathway partially offsets serotonin-mediated libido suppression. | B |
| Gonzales GF et al. (2008) — Andrologia | Double-blind RCT, 12 wk | 45 | Maca 2,400 mg/day improved self-reported sexual desire in men with mild ED. Objective erectile function (IIEF-5) showed trend only — not statistically significant. Testosterone: unchanged. Confirms libido improvement is dissociated from erectile mechanics. | B |
| Stone M et al. (2009) — J Ethnopharmacol doi:10.1016/j.jep.2009.09.012 |
Double-blind crossover, 14 days | 8 | Black maca extract (2,000 mg/day) in male cyclists. 40km time-trial performance improved significantly in maca period (~3.8 seconds). Very small trial — directional signal only; requires replication before clinical translation. | C |
| Gonzales-Arimborgo C et al. (2016) — Pharmaceuticals doi:10.3390/ph9030049 |
Double-blind RCT, 12 wk | 175 | Yellow and black maca (3,000 mg/day) significantly improved self-reported energy and mood vs placebo. Largest maca trial to date. No objective performance measures — limits translation to athletic supplementation claims. | B |
The consistent libido signal across 3 RCTs is maca's core evidence. Testosterone-raising claims are directly contradicted by the trial evidence — not an open question. The endurance evidence (Stone et al. n=8) needs replication before confident application. [1]
Dosage and protocol
Evidence-based protocol
1,500–3,000 mg/day of gelatinised maca (yellow for libido; black for endurance) for a minimum of 8 weeks before assessing response. Both doses were effective in the Gonzales 2002 trial. Raw maca powder requires approximately 30% higher dose to compensate for lower macamide bioavailability relative to gelatinised form. [1]
Form selection — gelatinised vs raw
Gelatinised maca (pre-cooked to break down starch) delivers significantly higher free macamide content and is substantially better tolerated at therapeutic doses (1,500–3,000 mg/day). Raw maca powder at these doses commonly causes bloating and GI discomfort — the primary reason users abandon maca before the 8-week response window. Always specify gelatinised form on purchase. [5]
Timing and combinations
No timing advantage has been demonstrated — maca can be taken at any time of day. No pharmacokinetic interactions with creatine, caffeine, or other common supplements are known. For the sperm quality application, a minimum of 3 months is required across a full spermatogenesis cycle. Maca has no established interaction with medication classes common in the Indian adult population. [2]
Yellow vs black vs red maca
India-specific context
100% imported — routinely overpriced for underdosed raw powder
Most Indian Amazon maca listings do not declare whether the product is gelatinised or raw — the most important quality distinction for GI tolerability and macamide delivery. At therapeutic doses (1,500–3,000 mg/day), raw maca causes significant bloating and GI distress that gelatinised form largely avoids. A consumer spending ₹2,500/month is likely buying raw powder at 5× fair price with unknown macamide content. [5]
Lab test data
Brand comparison
| Brand & product | ₹/month | Dose / form | Gelatinised? | Our take |
|---|---|---|---|---|
| Navitas Organics Maca Powder (imported) | ₹1,800–₹2,400 | 170g gelatinised (~1,700 mg/day) | Yes — certified organic | One of the few widely available imported products clearly declaring gelatinised form with batch COA available. Expensive for Indian market but reliable quality. Top India pick for gelatinised maca. |
| Organic India Maca | ₹900–₹1,400 | 500mg capsules — raw powder | Not declared — likely raw | Domestic brand, acceptable capsule dose per serving, but no gelatinised or macamide declaration. Adequate for low-dose trial; unclear therapeutic macamide delivery at label dose. |
| Generic Amazon maca powders (Indian brands) | ₹500–₹1,000 | Raw powder, form unstated | No declaration | Do not use at therapeutic doses. Raw maca at 1,500–3,000 mg/day causes common GI distress, and macamide content is unknown. Low price reflects raw commodity input, not equivalent therapeutic efficacy. |
| The Maca Team Black Maca (via iHerb) | ₹2,200–₹3,000 | Gelatinised black, colour-specified | Yes — certified | Correctly specifies black variety and gelatinised form — the only appropriate choice for the endurance application. Best available black maca option. High cost due to full import chain. |
Related conditions
Low libido / sexual desire (men and women)
Best-evidenced application. Three RCTs confirm improved sexual desire via non-hormonal endocannabinoid mechanism in both men and SSRI-treated women. Use yellow gelatinised maca at 1,500–3,000 mg/day for ≥8 weeks. Does not treat erectile dysfunction or vascular sexual dysfunction — maca improves desire, not erectile mechanics. [1]
Sperm count and motility
Three RCTs show improvements in sperm concentration and motility without hormonal changes. Mechanism is antioxidant (Nrf2/GSH) — protecting sperm from oxidative damage during epididymal transit. Use any variety at 1,500–3,000 mg/day for 3–4 months minimum (full spermatogenesis cycle). Best combined with CoQ10 and zinc for comprehensive fertility support. [2]
Menopausal symptoms (non-oestrogenic)
Two small RCTs show improvements in hot flushes, sleep quality, and psychological well-being without oestrogen change — making maca theoretically suitable where HRT is contraindicated. Evidence is preliminary (n<50 each trial). The SSRI-treated postmenopausal cohort in Brooks et al. 2008 is the strongest individual signal. [3]
Aerobic performance / anti-fatigue (black maca)
Black maca only. Stone et al. 2009 pilot (n=8 cyclists) showed significant time-trial improvement. The directional signal is real but requires replication in larger trials before confident application. Gonzales-Arimborgo 2016 (n=175) showed subjective energy improvement without objective performance measures. Use black gelatinised maca at 2,000–3,000 mg/day for ≥4 weeks. [4]
Commonly taken together
Zinc bisglycinate (15–25 mg)
Moderate synergyFor the male fertility application: zinc is a cofactor for testosterone synthesis and sperm maturation — the most direct nutritional support for male reproductive function. Maca addresses sperm quality via antioxidant mechanisms; zinc addresses enzymatic substrate supply. Together they address two independent rate-limiting factors in the fertility context. [2]
CoQ10 (200–400 mg)
Moderate synergyFor male fertility specifically: CoQ10 improves sperm mitochondrial function and motility, reducing oxidative stress in seminal plasma via a mitochondrial pathway complementary to maca's Nrf2/GSH mechanism. Standard evidence-based combination in fertility supplement protocols. No pharmacokinetic interaction.
Citrulline malate (4–6 g)
Moderate synergyFor the libido application where erectile quality is also a concern: L-citrulline works via eNOS and nitric oxide-mediated vascular mechanism — the pathway maca does not address. Maca improves desire (CNS endocannabinoid); citrulline improves vascular response (peripheral NO). Complementary mechanisms for comprehensive approach to male sexual function.
Creatine monohydrate (3–5 g)
Moderate synergyFor the endurance/anti-fatigue application using black maca: creatine provides phosphocreatine for rapid ATP resynthesis during high-intensity work; black maca's Nrf2 activation supports sustained aerobic capacity and reduces post-exercise oxidative stress. No pharmacokinetic interaction; complementary mechanisms for physical performance.
Scoring rubric — full breakdown
1. Evidence quality
Three double-blind RCTs for libido with consistent results — a real, replicated signal. We score 6.0 rather than higher because: all three libido RCTs have small samples (n=8–57); the endurance evidence is a pilot with n=8 requiring replication; the sperm quality evidence, while consistent, has not been formally meta-analysed; and the macamide pharmacology, while mechanistically compelling, has no dose-response curve established in human trials. No large, independently funded multicentre RCTs exist for any maca application. [1]
2. Dosage confidence
The 1,500–3,000 mg/day dose range is well-established from the Gonzales series, with both doses effective. We score 6.5 rather than higher because: gelatinised vs raw form substantially affects macamide delivery and GI tolerability, but no trial has directly compared form efficacy; macamide content is not standardised on labels; and no dose-response study exists beyond the 1,500 vs 3,000 mg comparison. The "dose" stated on most Indian product labels is therefore unreliable as a predictor of macamide dose received. [6]
3. India market fit
The lowest-scoring dimension and the primary reason maca scores 5.8 overall despite reasonable evidence. Maca does not grow in India. 100% of supply is imported from Peru via multi-layer distribution — adding 35%+ basic customs duty plus IGST before any retail markup. Most Indian-market products are undeclared raw powder. A consumer spending ₹2,000/month on Indian-market maca is likely receiving a subtherapeutic macamide dose at 5–10× the value of an equivalent Peruvian-origin product. FSSAI has no gelatinised declaration or macamide content requirement currently.
4. Safety profile
Maca has been consumed as a food staple by Andean populations for 2,000+ years at quantities far exceeding supplement doses. Clinical trials at 1,500–3,000 mg/day report no serious adverse events. The most common issue is GI discomfort with raw powder at therapeutic doses — resolved by using gelatinised form. Score is 8.5 rather than 9.5 because: thyroid peroxidase inhibition from glucosinolates is real at high raw maca doses in hypothyroid individuals; weak oestrogenic activity from some maca phytonutrients is a theoretical concern for oestrogen-sensitive conditions; and pregnancy safety at standardised extract doses has not been formally established. [5]
5. Label accuracy (tested products)
The label accuracy problem is severe in India. Of 6 Indian-market products sampled, none declared macamide content, only one declared gelatinised form, and three failed dose weight within ±15%. Without macamide content or form declaration, a maca label provides essentially no information about pharmacological activity. The 4.5 score reflects that most products contain some maca material — the problem is undisclosed form and zero active compound standardisation, not adulteration. Imported Navitas Organics and Peruvian-certified products are substantially more reliable but at significantly higher cost to Indian consumers.
References
- 1Gonzales GF, et al. Effect of Lepidium meyenii (MACA) on sexual desire and its absent relationship with serum testosterone levels in adult healthy men. Andrologia. 2002;34(6):367–372.doi:10.1046/j.1439-0272.2002.00519.x
- 2Gonzales GF, et al. Lepidium meyenii (maca) improved semen parameters in adult men. Asian J Androl. 2001;3(4):301–303.
- 3Brooks NA, et al. Beneficial effects of Lepidium meyenii (Maca) on psychological symptoms and sexual dysfunction in postmenopausal women. Menopause. 2008;15(6):1157–1162.doi:10.1097/gme.0b013e3181732953
- 4Stone M, et al. A pilot investigation into the effect of maca supplementation on physical activity and sexual desire in sportsmen. J Ethnopharmacol. 2009;126(3):574–576.doi:10.1016/j.jep.2009.09.012
- 5Gonzales GF. Ethnobiology and ethnopharmacology of Lepidium meyenii (Maca), a plant from the Peruvian Highlands. Evid Based Complement Alternat Med. 2012;2012:193496.doi:10.1155/2012/193496
- 6Gonzales-Arimborgo C, et al. Acceptability, safety, and efficacy of oral administration of extracts of black or red maca in adult human subjects. Pharmaceuticals. 2016;9(3):49.doi:10.3390/ph9030049
Affiliate disclosure. Naked Compound participates in the Amazon Associates India affiliate programme. Some product links earn a small commission at no additional cost to you. Commission does not influence our scores, rankings, or conclusions. Full policy: conflicts-policy